Singapore Heart Centre introduces photo-counting CT to enhance diagnostic precision for complex cardiac cases, offering a data-driven approach to improve patient outcomes through advanced imaging technology.
The Singapore Heart Centre’s adoption of photo-counting CT represents a pivotal advancement in cardiac diagnostics, leveraging photon-counting detectors to capture high-resolution, low-radiation images of coronary anatomy. This innovation addresses critical gaps in traditional computed tomography (CT), particularly in visualizing calcified plaques, microvascular disease, and coronary artery stenosis. By quantifying X-ray photons individually, the technology reduces noise and enhances contrast, enabling earlier detection of pathologies that might otherwise go undiagnosed with conventional methods.
How Photo-Counting CT Enhances Diagnostic Accuracy
Photo-counting CT operates on a principle distinct from standard CT, which relies on energy-integrating detectors. Instead, photon-counting systems measure the number and energy of individual X-ray photons, allowing for spectral imaging. This capability differentiates between materials like calcium, iodine, and soft tissue, which is critical in assessing atherosclerosis. A 2025 study in The Lancet Digital Health demonstrated that photon-counting CT improved diagnostic accuracy for coronary artery disease by 23% compared to conventional CT, with a 15% reduction in radiation exposure (Lancet Digital Health).
Regionally, this aligns with Singapore’s national goal to reduce cardiovascular mortality by 20% by 2030. Cardiovascular disease accounts for 32% of all deaths in Singapore, with ischemic heart disease being the leading cause (MOH). By adopting photo-counting CT, the Singapore Heart Centre aims to streamline triage for patients with complex cases, such as those with diabetes or chronic kidney disease, who often present with atypical symptoms.
Global Implications for Cardiac Care
The technology’s rollout in Singapore has broader implications for healthcare systems worldwide. In the U.S., the FDA has designated photon-counting CT as a “breakthrough device” under the Medical Device Innovation Consortium, accelerating its review for clinical use (FDA). Similarly, the European Medicines Agency (EMA) is evaluating its potential for reducing contrast agent use in patients with renal impairment, a population at high risk for contrast-induced nephropathy.
However, adoption faces hurdles. The initial cost of photon-counting CT systems is 3–5 times higher than conventional CT, raising concerns about equitable access. Dr. Anika R. Patel, a cardiovascular imaging specialist at the University of California, San Francisco, notes, “While the technology is revolutionary, its scalability depends on cost-effective manufacturing and training programs for radiologists.”
Funding and Ethical Considerations
The research behind photo-counting CT was funded by a consortium including the Singapore Ministry of Health, Siemens Healthineers, and the National Medical Research Council. This collaboration underscores the technology’s potential but also necessitates transparency to avoid conflicts of interest. A 2024 review in JAMA Internal Medicine emphasized that industry-funded trials often overestimate efficacy by 18–25% compared to independent studies (JAMA).
Despite these considerations, the technology’s benefits are undeniable. A phase III trial involving 1,200 patients across Asia, Europe, and North America reported a 92% sensitivity for detecting significant coronary stenosis, with a 7% lower false-positive rate than traditional CT (PubMed). These results support its integration into guidelines for
